Diamond Equity Research | Imugene Limited - Sustained Momentum with Key Clinical Advancements and Robust Financial Profile, With Numerous Upcoming Potential Catalysts
Diamond Equity Research | Imugene Limited – Receives Orphan Drug Designation for Bile Tract CancerTherapy and Reports Encouraging Blood Cancer Trial Outcomes
Bioshares - Imugene Delivers Positive Early Data with Azer-Cel Technology Acquired Last Year
Lodge Partners | Research Report Imugene Limited (ASX: IMU)
Roth Capital Partners | IMU: Azer-Cel Showing CRs In DLBCL Patients In Phase 1b Trial
Diamond Equity Research | IMU: Quarterly Report Highlights Significant Progress in Multiple Candidates, Strong Balance Sheet, and Numerous Upcoming Potential Clinical Catalysts
Roth Capital Partners | IMU: Phase 1 OASIS Solid Tumor Trial Starts Combination Therapy Dosing
Diamond Equity Research | IMU: Q3 FY2024 Update, Intellectual Property Milestones, and Meaningful Clinical Trial Advancements Anticipated in 2H 2024
Roth Capital Partners | IMU: General Quarterly Business Update, 2H24 To Be Rich In Clinical Data
Diamond Equity Research | IMU: Strategic Sale of North Carolina Facility and Clinical Trial Expansions Advancing
Bell Potter | Imugene Core Assets Progressing Nicely
Roth Capital Partners | IMU: Sells CGMP Facility That Manufactures Azer-cel, MAST Trial Making Progress
Diamond Equity Research | Imugene Financial Report Highlights Continuous Pipeline Progression and Other Strategic Advances
Roth Capital Partners | Clinical Progress With onCARlytics And VAXINIA In Solid Tumors
Diamond Equity Research | VAXINIA’s Releases Early Positive Data, PD1-Vaxx and Azer-cel Advancing Through Clinical Pipeline
ROTH Capital Partners | MAST Trial Evaluating VAXINIA Oncolytic Viral Yields More Positive Data
BIO SHARES | Investor Interest Starts Return to Biotech Sector
BIO SHARES | First Results for Imugene's Oncolytic Virus CF33
Bell Potter: No Time To Waste – Azer-cel Back In The Clinic
Valuation $0.15
ROTH•MKM IMU: Positive Initial VAXINIA MAST Trial Data, Expanding Bile Duct Tumor Cohort
12-month target: AUD0.46
DIAMOND EQUITY RESEARCH | Immuno-oncology Innovations Highlighted at ESMO, Financial Position Strengthened, and Clinical Pipeline Advancing
Valuation: A$0.49
ROTH•MKM IMU: Initiates Dosing In First Cancer Trial Combining onCARlytics With Blincyto
12-month target: AUD0.46
ROTH•MKM | IMU: 3 ESMO Posters Highlight HER-Vaxx & Oncolytic Virus CF33-hNIS-antiPD-L1
12-month target: AUD0.51
ROTH•MKM | IMU: Licenses Clinical Stage Allogeneic CD19 CAR T For Liquid Tumors
12-month target: AUD0.71
DIAMOND EQUITY RESEARCH | Imugene Secures Promising Allogeneic CAR-T Cell Therapy Asset, Expanding Pipeline and Addressable Market
Valuation: A$0.54
ROTH•MKM | U.S. Oncolytic Virus Patent Allowed, Enrolling 4th CHECKvacc Dose Cohort
12-month target: AUD0.71
ROTH•MKM | Doses First Combination NSCLC Patient in PD1-Vaxx + Tecentriq Phase 1/1b
12-month target: AUD0.71
DIAMOND EQUITY RESEARCH | IND Clearance Enables OnCARlytics to enter Human Clinical Trials
Valuation: A$0.46
31 May 2023
BELL POTTER | First In Human Trial For onCARlytics
19 May 2023
BIO SHARES | Imugene: Nine Clinical Programs to Advance in 2023
6 April 2023
DIAMOND Equity Research | H1 FY2023 Financial Result Update and Progress with Clinical Trials
Valuation: 46c AUD
6 March 2023
ROTH Capital Partners | Updating Financial Model Following Release of FY1H23 Financials
12 month price target: 71c AUD
23 February 2023
DIAMOND Equity Research | Initial Clinical Trial Data Encouraging with Strong Financial Position
Valuation: 46c AUD
30 January 2023
ROTH Capital Partners | IMU: Presents First Two CHECKVacc DoseCohorts at SABCS, Showing Clean Safety
12 month price target: 71c AUD
11 December 2022
ROTH Capital Partners | Favorable Phase 2 HER-Vaxx DoR Data Presented at the ESMO Asia Congress
12 month price target: 71c AUD
5 December 2022
DIAMOND EQUITY RESEARCH | OnCARlytics Pre-Clinical Highlights and Continued Progress on Multiple Fronts
Valuation: 46c AUD
23 November 2022
DIAMOND EQUITY RESEARCH | Therapeutic Cancer Vaccines and Oncolytic Virus Powered Immunotherapies Targeting Solid Tumors
Price Target 48c USD
29 September 2022
ROTH Capital Partners | Recent Clinical Highlights from Last Week Underscore Continued Progress
Price Target 71c AUD
14 August 2022
ROTH Capital Partners | Highly Positive Final Phase 2 HER-VaxxSurvival Data Justifies More Trials
Price Target 71c AUD.
27 June 2022
Noble Life Science Partners | Progress Continues With New Trial and ASCO Abstracts
Price target 50c USD.
1 June 2022
ROTH Capital Partners | First Phase 1 Advanced Solid Tumor Patient Dosed with CF33-hNIS VAXINIA
12-month share price target 71c AUD.
18 May 2022
ROTH Capital Partners | CHECKvacc Enters Second Dose Cohort, Cleared to Start U.S. VAXINIA Phase 1.
12-month share price target 71c AUD.
24 March 2022
ROTH Capital Partners | IMU.AX: Supply Deal with Merck KGaA & PFE for BAVENCIO/Chemo/HER-Vaxx Ph2 Trial. We raise our PT to AUD0.71 from AUD0.62.
16 November 2021
ROTH Capital Partners | IMU.AX: Solid Tumor Partnership with Eureka Therapeutics, Raising PT to AUD0.62
1 November 2021
BELL POTTER | HER-vaxx Program To Expand. Target 52 cents.
2 September 2021
BioShares | Bioshares 900 Special Edition: Top 10 Events in Australian Biotech in the Last 100 Editions
#7. Imugene - The Most Recent Billion Dollar Biotech Raises $90 Million
25 August 2021
BioShares | Imugene Secures $90 Million Transformational Capital Raise
11 August 2021
ROTH Capital Partners | IMU.AX: IND Cleared for U.S. Phase 1 Trial Initiation with CHECKvacc in TNBC
6 July 2021
ROTH Capital Partners | IMU: Licenses Oncolytic Virus That Enables CAR T Therapy to Target Solid Tumors
18 May 2021
ROTH Capital Partners | IMU: Efficacy & No Safety Issues in Second PD1-Vaxx Dose Cohort; Third Starting
7 April 2021
ROTH Capital Partners | IMU.AX 1H21 Results: Solid HER-Vaxx & PD1-
Vaxx Clinical Progress Despite COVID
8 March 2021
BELL POTTER | Imugene (IMU) HER-2 VAXX shows 5.4m OS benefit
Investment View: Retain Buy (Speculative)
3 December 2020
ROTH Capital Partners | Imugene Limited IMU.AX - $0.13 - ASX | BUY
IMU.AX: Initiates Phase 1 Dosing With PD1-Vaxx in NSCLC
1 December 2020
Pharma and Biotech Newsletter | IMU was the second best performing stock in the index in November, with the share price increasing 114.3%.
November 2020
ROTH Capital Partners | Imugene Limited IMU.AX - $0.13 - ASX | BUY
IMU.AX: Interim Phase 2 Data Show HERVaxx OS Benefit, Raising PT to $0.20
23 November 2020
ROTH Capital Partners | Imugene Limited IMU.AX - AUD0.06 - ASX | Buy IMU.AX
1QFY21 Cash Flows, PD1-Vaxx IND Cleared in U.S., U.S. Patent Granted
11 November 2020
ROTH Capital Partners | Imugene Limited IMU.AX - AUD0.05 - ASX | Buy IMU.AX
Engineered Oncolytic Viruses and B Cell Immunotherapies to Fight Cancer
01 October 2020
Bell Potter | Imugene (IMU) Deep Pipeline, Max Potential
The Future Of Cancer Therapy
13 May 2020
BioShares | Imugene Well Positioned With $34 Million in Cash
Page 5.
May 11, 2020
BioShares | Imugene Expanding Oncology Pipeline
November 11, 2019
BioShares | Imugene To Expand Portfolio With License of Oncolytic Virotherapy
July 22, 2019
Edison Research Note | In-Licensing deal for CF33 oncolytic virus
July 15, 2019
Australian Research Independent Investment Research | Imugene Limited (ASX: IMU) Initiating Coverage
July 15, 2019
Edison Research Note | HER-Vaxx Phase II underway
April 15, 2019
BioShares | Imugene prepares for Phase IIa Study
September 14, 2018
Edison Research Note | Checkpoint inhibitor vaccine programme accelerated
August 16, 2018
BioWorld | Aussie biotech Imugene leads pack in HER2-targeting B-cell immunotherapies
January 22, 2018
BioShares | Imugene Set To Commence Phase Ib/II Gastric Cancer Trial
June 3, 2016
Red Chip Research Report | Anti-tumour vaccine trial to start mid-2016
April 18, 2016
Edison Research Note | Anti-tumour vaccine trial to start mid-2016
February 19, 2016
BioShares | Imugene Adopts a Portfolio Model to Become a B Cell Vaccines Play
January 22, 2016